Relationship of the systemic level of chemerin and clinical - laboratory parameters in patients with rheumatoid arthritis
https://doi.org/10.25789/YMJ.2023.83.08
Abstract
Objective: to study the relationship between the level of chemerin in blood serum and clinical and laboratory parameters of patients with RA.
Materials and methods. We observed 88 women diagnosed with RA, the average age was 56.4 years [47.5-60.7]. Disease activity according to DAS 28 was 3.50±1.11 (3.27-3.74) points. Articular erosions were present in 69 (78.4%) patients. Serum chemerin levels were determined using the commercial HUMAN CHEMERIN ELISA kit (BioVendor). Statistical processing was performed using the Statistica 12.0 software package for Windows.
Results. The average level of chemerin in patients with RA was 463.5 ng/mL [366-576.5]. The level of chemerin in the blood serum has a direct correlation with the weight and BMI of patients, with the number of painful joints, as well as with the average annual dose of corticosteroids. The average concentration of chemerin in patients with an early stage of RA was significantly higher than in patients with an advanced stage (p=0.037). The difference between the level of chemerin in patients with early and late stages of RA is also close to statistically significant (p=0.066). The level of chemerin is significantly higher in RA patients with diabetes mellitus (p=0.007). The relationship was found chemerin with the level of CRP (Spearman - R=0.272758, p=0.010139). No correlations were found between the concentration of chemerin in the blood serum and the state of the bone tissue.
It can be assumed that chemerin is a typical pro-inflammatory adipokine that modulates inflammation in RA. In our study, in patients with RA, a positive correlation was found between the level of chemerin and weight, as well as BMI of patients. The level of chemerin is significantly higher in RA patients with diabetes mellitus.
About the Authors
Yu. R. Akhverdyan
Federal State Budgetary Institution Research Institute of Clinical and Experimental Rheumatology (FSBI RICER)
Russian Federation
Russian Federation
AKHVERDYAN Yuri Rubenovich – PhD, senior researcher at the Laboratory of Methods for the Treatment and Prevention of Joint Diseases
Volgograd
E. V. Papichev
Federal State Budgetary Institution Research Institute of Clinical and Experimental Rheumatology (FSBI RICER)
Russian Federation
Russian Federation
PAPICHEV Evgeny Vasilyevich – PhD, research associate at the Laboratory for Methods of Treatment and Prevention of Joint Diseases
Volgograd
B. V. Zavodovsky
Federal State Budgetary Institution Research Institute of Clinical and Experimental Rheumatology (FSBI RICER)
Russian Federation
Russian Federation
ZAVODOVSKY Boris Valeryevich – MD, Deputy director, head of the laboratory of methods of treatment and prevention of joint diseases
Volgograd
J. V. Polyakova
Federal State Budgetary Institution Research Institute of Clinical and Experimental Rheumatology (FSBI RICER)
Russian Federation
Russian Federation
POLYAKOVA Yulia Vasilyevna – PhD, research associate
Volgograd
L. E. Seewordova
Federal State Budgetary Institution Research Institute of Clinical and Experimental Rheumatology (FSBI RICER)
Russian Federation
Russian Federation
SEEVORDOVA Larisa Evgenievna – PhD, visiting researcher leading researcher at the laboratory of methods for the treatment and prevention of joint diseases
Volgograd
References
1. Batyushin M.M. Chemerin. Role in regulation of inflammation and study of significance in nephrology // Nefrologiya. 2014;18(5):8-15.
2. Chemerin activates fibroblast-like synoviocytes in patients with rheumatoid arthritis / Kaneko K. [et al.] // Arthritis Res. Ther. 2011. 13(5), R158. doi 10.1186ar3475.
3. Chemerin in inflammatory diseases / Su X. [et al.] // Clin Chim Acta. 2021; Jun;517:41-47. doi: 10.1016/j.cca.2021.02.010.
4. Chemerin induces CCL2 and TLR4 in synovial fibroblasts of patients with rheumatoid arthritis and osteoarthritis / Eisinger K. [et al.] // Exp Mol Pathol. 2012;92:90–6. doi: 10.1016/j.yexmp.2011.10.006.
5. Chemerin regulation and role in host defense / Zabel B.A. [et al.] // Am J Clin Exp Immunol. 2014;3(1):1-19.
6. Chemerin: A Functional Adipokine in Reproductive Health and Diseases / Yu M. [et al.] // Biomedicines. 2022; 10(8):1910. doi: 10.3390/biomedicines10081910.
7. Ferland D.J., Mullick A.E., Watts S.W. Chemerin as a Driver of Hypertension: A Consideration // Am J Hypertens. 2020 Nov 3;33(11):975-986. doi: 10.1093/ajh/hpaa084.
8. Functional disability is related to serum chemerin levels in rheumatoid arthritis / Vazquez-Villegas M.L. [et al.] // Sci Rep 11, 8360 (2021) doi: 10.1038/s41598-021-87235-6
9. Handbook of Biologically Active Peptides edited by Abba J. Kastin (Second Edition), 2013.
10. Healthcare (Basel) / Jiménez-Martínez P. [et al.] // 2023 Feb 16;11(4):594. doi: 10.3390/healthcare11040594.
Review
For citations:
Akhverdyan Yu.R., Papichev E.V., Zavodovsky B.V., Polyakova J.V., Seewordova L.E. Relationship of the systemic level of chemerin and clinical - laboratory parameters in patients with rheumatoid arthritis. Yakut Medical Journal. 2023;(3):33-36. https://doi.org/10.25789/YMJ.2023.83.08
Views:
28
Email this article 